• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director White Robert S. exercised 10,000 shares at a strike of $22.62, increasing direct ownership by 10% to 106,773 units (SEC Form 4)

    5/7/25 8:25:11 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care
    Get the next $ATRC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    WHITE ROBERT S.

    (Last) (First) (Middle)
    9060 ROCKY POINT DRIVE

    (Street)
    VERO BEACH FL 32963

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AtriCure, Inc. [ ATRC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/05/2025 M 10,000 A $22.62 106,773 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Non-qualified Stock Option (right to buy) $22.62 05/05/2025 M 10,000 05/20/2016(1) 05/20/2025 Common Stock 10,000 $22.62 0 D
    Explanation of Responses:
    1. These options were granted on May 20, 2015. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.
    Remarks:
    /s/ Robert S. White 05/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATRC

    DatePrice TargetRatingAnalyst
    12/17/2024$40.00Overweight
    Analyst
    4/23/2024$32.00Perform → Outperform
    Oppenheimer
    10/23/2023$60.00Mkt Outperform
    JMP Securities
    9/29/2023$56.00Buy
    UBS
    2/16/2022$120.00 → $88.00Buy
    Canaccord Genuity
    2/16/2022$92.00 → $79.00Buy
    Needham
    11/4/2021$90.00 → $92.00Buy
    Needham
    11/4/2021$100.00 → $110.00Outperform
    SVB Leerink
    More analyst ratings

    $ATRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AtriCure Reports First Quarter 2025 Financial Results

      Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. "Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business," said Michael Carrel, President and Chief Executiv

      4/29/25 4:01:00 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Announces First Use of the AtriClip PRO-Mini® Device

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ® device for minimally invasive concomitant procedures, the AtriClip PRO-Mini® LAA Exclusion System. The AtriClip PRO-Mini device received FDA 510K clearance earlier this year and is a testament to AtriCure's commitment to innovating the lowest profile and most effective surgical LAA devices on the market. Building upon the proven technology of AtriCure's AtriClip platform as the most widely implanted surgical LAA device globally, the AtriClip PRO-Mini

      4/10/25 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure to Announce First Quarter 2025 Financial Results

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://

      4/8/25 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Financials

    Live finance-specific insights

    See more
    • AtriCure Reports First Quarter 2025 Financial Results

      Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. "Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business," said Michael Carrel, President and Chief Executiv

      4/29/25 4:01:00 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure to Announce First Quarter 2025 Financial Results

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://

      4/8/25 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

      Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE®+, cryoSPHERE MAX™ and AtriClip® FLEX-Mini™ devices in the United States, and EnCompass® clamp in Europe AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. "2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profi

      2/12/25 4:01:00 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ATRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director White Robert S. exercised 10,000 shares at a strike of $22.62, increasing direct ownership by 10% to 106,773 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      5/7/25 8:25:11 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • President, CEO, & Director Carrel Michael H gifted 4,000 shares, decreasing direct ownership by 0.56% to 706,555 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      3/12/25 4:22:31 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • Director Prange Karen sold $232,532 worth of shares (6,100 units at $38.12), decreasing direct ownership by 25% to 17,828 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      3/7/25 8:21:26 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by AtriCure Inc.

      SC 13G - AtriCure, Inc. (0001323885) (Subject)

      11/14/24 8:00:04 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

      SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

      2/14/24 2:56:38 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

      SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

      2/13/24 4:58:56 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    SEC Filings

    See more
    • SEC Form DEFA14A filed by AtriCure Inc.

      DEFA14A - AtriCure, Inc. (0001323885) (Filer)

      5/5/25 4:20:55 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by AtriCure Inc.

      10-Q - AtriCure, Inc. (0001323885) (Filer)

      4/30/25 1:06:24 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AtriCure, Inc. (0001323885) (Filer)

      4/29/25 4:00:17 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Leadership Updates

    Live Leadership Updates

    See more
    • AtriCure Appoints Shlomi Nachman to the Board of Directors

      AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck

      1/4/24 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo

      6/1/22 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Privitera Salvatore bought $111,250 worth of shares (5,000 units at $22.25), increasing direct ownership by 5% to 103,290 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      5/31/24 4:12:34 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst resumed coverage on AtriCure with a new price target

      Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00

      12/17/24 7:29:01 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00

      4/23/24 6:23:54 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • JMP Securities initiated coverage on AtriCure with a new price target

      JMP Securities initiated coverage of AtriCure with a rating of Mkt Outperform and set a new price target of $60.00

      10/23/23 7:18:47 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care